International Health
Volume 1, Issue 2 , Pages 163-168 , December 2009

Perceptions on onchocerciasis and ivermectin treatment in rural communities in Uganda: implications for long-term compliance

  • Richard Ndyomugyenyi

      Affiliations

    • Ministry of Health, P.O. Box 7272, Kampala, Uganda
    • Corresponding Author InformationCorresponding author. Tel.: +256 772 457980; fax: +256 41 348339.
    • ,
  • Andrew Byamungu

      Affiliations

    • Ministry of Health, P.O. Box 7272, Kampala, Uganda
    • ,
  • Rose Korugyendo

      Affiliations

    • Uganda Management Institute, P.O. Box 20131, Kampala, Uganda

Received 22 April 2009 ,Revised 19 June 2009 ,Accepted 13 August 2009.

References 

  1. Kipp W, Bamuhiiga J. Onchodermal skin disease in a hyperendemic onchocerciasis focus in Western Uganda. Am J Trop Med Hyg. 2002;67:475–479
  2. Fischer P, Kip W, Bamuhiinga J, Binta-Kahwa J, Kiefer A, Büttner DW. Parasitology and clinical characterization of Simulium neavei-transmitted onchocerciasis in western Uganda. Trop Med Parasitol. 1993;44:311–321
  3. WHO. The importance of onchocercal skin diseases. Geneva: World Health Organization; 1995, TDR/ONCHO/95.1.
  4. Amazigo UO. Detrimental effects of onchocerciasis on marriage age and breast-feeding. Trop Geogr Med. 1994;46:322–325
  5. Okello DO, Ovuga EB, Ogwal JW. Dermatological problems of onchocerciasis in Nebbi district, Uganda. East Afr Med J. 1995;72:295–298
  6. Ovuga EB, Okello D, Ogwal Okeng JW, Orwortho N, Opoka FO. Social and psychological aspects of onchocercal skin disease in Nebbi district, Uganda. East Afr Med J. 1995;72:449–453
  7. World Bank. African Programme for Onchocerciasis Control: Programme Document. Committee of Sponsoring Agencies. Washington: World Bank; 1996;
  8. Brieger WR, Awedoba AK, Eneanya CI, Hagan M, Ogbuagu KF, Okello DO, et al. The effects of ivermectin on onchocercal skin disease and severe itching: results of multi-centre trial. Trop Med Int Health. 1998;3:951–961
  9. Winnen M, Plaisier AP, Alley ES, Nagelkerke NJD, van Oortmarssen G, Boatin BA, et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa?. Bull World Health Organ. 2002;80:384–390
  10. Richard FO, Hopkins DR, Cupp E. Varying programmatic goals and approaches to river blindness. Lancet. 2000;255:1663–1664
  11. Burnham G, Mebrahtu T. Review: The delivery of ivermectin (Mectizan). Trop Med Int Health. 2004;9:A26–44
  12. Akogun OB, Akogun MK, Audu Z. Community perceived benefits of ivermectin treatment in northeastern Nigeria. Soc Sci Med. 2000;50:1451–1456
  13. Emukah EC, Osuoha E, Miri ES, Onyenama J, Amazigo U, Obijuru C, et al. A longitudinal study of impact of repeated mass treatment on clinical manifestation of onchcoerciasis in Imo State, Nigeria. Am J Trop Med Hyg. 2004;70:556–561
  14. Ndyomugyenyi R, Tukesiga E, Büttner DW, Garms R. The impact of ivermectin treatment alone and when in parallel with Simulium neavei elimination on onchocerciasis in Uganda. Trop Med Int Health. 2004;9:882–886
  15. Vlassoff C, Weiss M, Ovuga EBL, Eneanya C, Nwel PT, Babalola SS, et al. Gender and the stigma of onchocercal skin disease in African. Soc Sci Med. 2000;50:1353–1368
  16. Dimomfu BL, Kayembe DL, Noma M, Sékétéli A, Boussinesq M. African Programme for Onchocerciasis Control (APOC): sociological study in three foci of central Africa before the implementation of treatments with ivermectin (Mectizan ®). Trans R Soc Trop Med Hyg. 2007;101:674–679
  17. Oladepo O, Brieger WR, Otusanya S, Kale OO, Offiong S, Titiloye M. Farm land size and onchocerciasis status of peasant farmers in South-Western Nigeria. Trop Med Int Health. 1997;2:334–340
  18. Benton B, Bump J, Sékétéli A, Liese B. Partnership and promise: evolution of the African river-blindness campaigns. Ann Trop Med Parasitol. 2002;96(Suppl):S5–14
  19. Nnoruka EN, Agu CE. Successful treatment of scabies with oral ivermectin in Nigeria. Trop Doct. 2001;31:15–18
  20. Njoo FL, Belling AC, Oosting J, Vetter JC, Stilma JS, Kijlsta A. Concurrent parasitic infections in onchocerciasis and the occurrence of adverse reactions after ivermectin treatment. Am J Trop Med Hyg. 1993;48:652–657
  21. Olsen A, Magnussen P, Ouma JH, Andreassen J, Friis H. The contribution of hookworm and other parasitic infections to haemoglobin and iron status among children and adults in western Kenya. Trans R Soc Trop Med Hyg. 1998;92:643–649
  22. Ndyomugyenyi R, Kabatereine N, Oslen A, Magnussen P. Malaria and hookworm infections in relation to haemoglobin and serum ferritin levels in pregnancy in Masindi district, western Uganda. Trans R Soc Trop Med Hyg. 2008;102:130–136
  23. Brieger WR, Otusanya SA, Oke GA, Oshinawe FO, Adeniyi JD. Factors associated with coverage in community-directed treatment with ivermectin for onchocerciasis control in Oya State, Nigeria. Trop Med Int Health. 2001;7:11–18
  24. Semiyaga NB, Lalobo O, Ndyomugyenyi R. Refusal to ivermectin treatment; the associated risk factors in Hoima district, Uganda. Ann Trop Med Parasitol. 2005;99:659–667
  25. Nuwaha F, Okware J, Ndyomugyenyi R. Predictors of compliance with community-directed ivermectin treatment in Uganda: quantitative results. Trop Med Int Health. 2005;7:659–667
  26. Katabarwa N, Mutabazi D, Richards FO. Controlling onchocerciasis by community directed, ivermectin treatment programmes in Uganda: why do some communities succeed and others fail?. Ann Trop Med Parasitol. 2000;94:343–352
  27. Escott S, Walley J. Listening to those on the frontline: Lessons for community-based tuberculosis programmes from a qualitative study in Swaziland. Soc Sci Med. 2005;61:1701–1710

PII: S1876-3413(09)00036-9

doi: 10.1016/j.inhe.2009.08.008

International Health
Volume 1, Issue 2 , Pages 163-168 , December 2009

Article Tools

* Image Usage & Resolution